Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice
Authors:
- 14 October 2022
- journal article
- research article
- Published by Elsevier in Journal of Cardiology
- Vol. 81 (4) , 347-355
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (19K08495)
This publication has 37 references indexed in Scilit:
- Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial HypertensionCirculation Research, 2014
- Pulmonary Hypertension Due to Left Heart DiseasesJACC, 2013
- Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertensionEuropean Respiratory Journal, 2013
- Tofogliflozin, a novel sodium–glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db miceBritish Journal of Pharmacology, 2013
- Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertensionRespiratory Research, 2011
- Pulmonary hypertension with left-sided heart diseaseNature Reviews Cardiology, 2010
- Prognostic Importance of Pulmonary Hypertension in Patients With Heart FailureThe American Journal of Cardiology, 2007
- Intracellular pH as a Determinant of Vascular Smooth Muscle FunctionJournal of Vascular Research, 2006
- Chronic hypoxia elevates intracellular pH and activates Na+/H+exchange in pulmonary arterial smooth muscle cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2005
- Adiponectin-mediated modulation of hypertrophic signals in the heartNature Medicine, 2004